Nelson Advisors invited to join the ‘HealthTech predictions for 2026’ panel at HealthTechX on 5th November 2025

HealthTechX 2025
 
The HealthTechX 2025 Summit is a one-day event taking place on November 5, 2025, at The Hurlingham Club in London. It's a key gathering for leaders in the health technology sector, including CEOs, founders, investors, and policymakers.
  
Agenda and Key Themes

The summit's agenda focuses on how technology is transforming healthcare with a tangible impact. Confirmed session topics include:
  
AI-driven diagnostics: Exploring the latest advancements and applications of artificial intelligence in medical diagnosis.

The healthcare workforce gap: Discussing how technology can help address the shortage of healthcare professionals.

Medical robotics: Showcasing innovations in robotics and their role in improving patient care and surgical procedures.

Specific confirmed sessions for the 2025 event include:
 
Beyond the Hype - AI's Place in Healthcare

The Evolution of Telehealth in a Post-COVID World

Hospital to Home - Enabling the Continuum of Care

From Prescription to Prevention - The Challenge of Lifestyle Change

Mental Health and Prevention

Hearing from the Investors

Speakers and Attendees

The event brings together leaders from across the health technology ecosystem. Past and confirmed speakers represent a wide range of organizations, from pharmaceutical and tech giants to innovative startups and investment firms. Attendees can expect to network with individuals from companies such as Merck, IBM, Philips, Takeda, Roche, and AstraZeneca.

https://impactx2050.com/healthtechx

Nelson Advisors HealthTechX 2025

Healthtech predictions for 2026 Panel

Nelson Advisors Partner Lloyd Price will join fellow panellists Stuart Peak, CEO at HeliosX, Farhan Ismail Associate Director, Office for Digital Health at NICE and Sneh Khemka, Executive Director at NEOM and Venture Partner at Archimed Health covering key questions such as:

Will investors continue to rigidly prioritise profitability and sustainable revenue models over aggressive expansion, forcing a large number of undercapitalised early-stage HealthTech companies to exit via M&A or shut down in 2026?

Will 2026 see a dramatic increase in the consolidation of fragmented HealthTech point solutions? Specifically, will large strategic players (e.g., major hospital groups, Pharma, or Big Tech) acquire European startups to build out their own integrated digital infrastructure, leading to a new class of multi-billion dollar exits?

To what extent will the EU AI Act's "high-risk" classification for most medical AI systems slow down the deployment of AI solutions (such as diagnostic tools) in 2026, and will the accompanying guidelines (due in early 2026) provide the necessary clarity for compliance?

How quickly will Member States align their national data frameworks with the EHDS, and by 2026, will this new infrastructure actually unlock the secondary use of health data for AI training and research at scale, or will fragmentation persist?

Will the increasing use of medical-grade biosensors, wearables, and genomic data lead to a significant commercial inflection point for highly personalized or preventive medicine platforms, demonstrating superior health economic outcomes (eg. cost reduction in managing chronic diseases)?

To discuss how Nelson Advisors can speak on a panel, chair the discussions or attend  your MedTech or HealthTech event, please email [email protected]